Skip to main content

Market Overview

UPDATE: Piper Jaffray Upgrades Questcor Pharmaceuticals Following Strong 2Q13 Report

Share:

In a report published Wednesday, Piper Jaffray analyst David Amsellem upgraded Questcor Pharmaceuticals (NASDAQ: QCOR) from Neutral to Overweight, and raised the price target from $41.00 to $74.00.

In the report, Piper Jaffray noted, “In the wake of a very strong 2Q13 for Questcor (non-GAAP diluted EPS was $1.35, well above the Street estimate of $1.00), we are upgrading the shares to Overweight from Neutral and raising our PT to $74 from $41. There is clear evidence of Acthar expansion in the rheumatology setting. This dynamic, coupled with prescription (Rx) stability (at a minimum) in other treatment settings where Acthar has been historically used (e.g., nephrotic syndrome (NS)) and the absence of evidence of any new restrictions from managed care justifies upward revisions to our estimates and P/E expansion in our view. With cash flows looking increasingly sustainable (and likely to grow) longer-term, we believe a P/E closer to the 2015 average of 14x for QCOR's brand specialty pharma peers is appropriate, particularly considering the complexities associated with the product that make generic competition a remote possibility.”

Questcor Pharmaceuticals closed on Tuesday at $51.91.

Latest Ratings for QCOR

DateFirmActionFromTo
May 2014MizuhoDowngradesBuyNeutral
May 2014PiperJaffrayDowngradesOverweightNeutral
Apr 2014JefferiesDowngradesBuyHold

View More Analyst Ratings for QCOR
View the Latest Analyst Ratings

 

Related Articles (QCOR)

View Comments and Join the Discussion!

Posted-In: David Amsellem Piper JaffrayAnalyst Color Upgrades Analyst Ratings

Latest Ratings

StockFirmActionPT
HSTOCanaccord GenuityInitiates Coverage On5.0
OKTADeutsche BankMaintains270.0
AGCODeutsche BankMaintains145.0
SHAKDeutsche BankMaintains107.0
OKTAMizuhoMaintains255.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com